Gentian Diagnostics AS's ROE % for the quarter that ended in Mar. 2026 was -41.61%. Gentian Diagnostics AS's PB Ratio for the quarter that ended in Mar. 2026 was 3.18.
Gentian Diagnostics AS's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -13.08%.
Gentian Diagnostics AS ROE % Adjusted to Book Value Related Terms
Gentian Diagnostics AS ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Gentian Diagnostics AS's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gentian Diagnostics AS ROE % Adjusted to Book Value Chart
OSL:GENT vs ABT, SYK, MDT: ROE % Adjusted to Book Value Comparison
For the Medical Devices subindustry, Gentian Diagnostics AS's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gentian Diagnostics AS ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Gentian Diagnostics AS's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -13.08% mean?
Gentian Diagnostics AS (OSL:GENT) has a ROE % Adjusted to Book Value of -13.08% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Gentian Diagnostics AS and its competitors.
Is Gentian Diagnostics AS's ROE % Adjusted to Book Value too high?
Gentian Diagnostics AS's current ROE % Adjusted to Book Value is -13.08%. Overall, Gentian Diagnostics AS has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's ROE % Adjusted to Book Value compare to ABT and SYK?
Gentian Diagnostics AS's ROE % Adjusted to Book Value of -13.08% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Gentian Diagnostics AS and its competitors. Gentian Diagnostics AS's current ROE % Adjusted to Book Value is -13.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSL:GENT) is currently considered Possible Value Trap. The stock's GF Value™ is kr61.81, compared to a current price of kr37.00 — trading 40.1% below its estimated fair value. The current ROE % Adjusted to Book Value is -13.08%. Gentian Diagnostics AS's overall GF Score™ is 72/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Gentian Diagnostics AS (OSL:GENT), the current ROE % Adjusted to Book Value is -13.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?
Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued.
The current stock price of kr37.00 is trading 40.1% below its estimated GF Value™ of kr61.81.
GuruFocus considers Gentian Diagnostics AS to be Possible Value Trap.
Key valuation signals for OSL:GENT:
ROE % Adjusted to Book Value: -13.08%
GF Value™: kr61.81 vs. price of kr37.00 (40.1% below fair value)
No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
72GF Score
Get the complete analysis for OSL:GENT
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:GENT has been successfully added to your 
